GEM21S Growth Factor Enhanced Matrix Implementation of Restricted Access Barrier System (RABS) at Pyramid
Lynch Biologics, LLC · Decision date Aug 3, 2026
What did the FDA approve?
FDA records P040013/S033 as a supplement to PMA P040013, with the supplement type “135 Review Track For 30-Day Notice”. The recorded decision is approval, dated Aug 3, 2026.
FDA approval order statement
implementation of a Restricted Access Barrier System (RABS) to the syringe filler unit for the filling of the rhPDGF-BB syringe component of GEM21S
- Regulatory pathway
- PMA supplement
- Supplement type
- 135 Review Track For 30-Day Notice
- Clinical specialty
- Dental
- Decision date
- Aug 3, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P040013/S033
- Regulatory pathway
- PMA supplement
- Applicant
- Lynch Biologics, LLC
- Product code
- NPZ
- Decision code
- APPR
- Decision date
- Aug 3, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Bone grafting material, dental, with biologic component.
- Applicant
- Lynch Biologics, LLC
- Product code
- NPZ
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P040013/S033 received
Application receipt date recorded by FDA.
P040013/S033 · FDA decision
135 Review Track For 30-Day Notice
Timeline entries are records held by MedtechLedger for P040013. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code NPZ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
INFUSE BONE GRAFTP050053/S066 | Medtronic, Inc. | PMA supplement | Aug 26, 2026 | FDA |
Infuse Bone GraftP050053/S069 | Medtronic, Inc. | PMA supplement | Jul 28, 2026 | FDA |
INFUSE Bone GraftP050053/S068 | Medtronic, Inc. | PMA supplement | Mar 19, 2026 | FDA |
INFUSE Bone GraftP050053/S067 | Medtronic, Inc. | PMA supplement | Feb 24, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Lynch Biologics, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 5526 Joseph St., Franklin, TN, 37064
Sources and methodology
- Original FDA record: P040013/S033
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


